Clinical trial · Observational
Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute
NCT03098576CI-TRIAL-00074737completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to examine the usefulness of matching patients to targeted therapy by analyzing a tumor sample taken at diagnosis and testing it against 50 cancer-associated genes. Targeted therapy is a highly personalized, newer approach to cancer treatment that aims to more precisely identify and attack cancer cells, in an effort to do less damage to normal cells.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Matched targeted drug treatment | Other | — | UNRESOLVED |
| Unmatched standard of care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Matched
- description
- Matched targeted drug treatment
- interventionNames
- Other: Matched targeted drug treatment
- label
- Control
- description
- Unmatched standard of care
- interventionNames
- Other: Unmatched standard of care
Primary outcomes (1)
- measure
- Response rate
- timeFrame
- 3 years
- description
- To evaluate the proportion of patients with response to targeted study agent(s) in patients with advanced cancers.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced and metastatic solid tumors who have failed standard treatments known to improve survival * Female and male adults age 18 and older. * ECOG PS 0-2 * Acceptable hematological, renal, or liver function * Patients planning to undergo a systemic treatment * Written informed consent obtained from subject and ability for subject to comply with the requirements of the study. Exclusion Criteria: * Significant comorbidities that could interfere with the study (compliance and visits)
References
Publications (0)
Data not yet available
No reference posted for this study.